KR20150024843A - 비소세포 폐암을 치료하는 방법 - Google Patents

비소세포 폐암을 치료하는 방법 Download PDF

Info

Publication number
KR20150024843A
KR20150024843A KR20147035652A KR20147035652A KR20150024843A KR 20150024843 A KR20150024843 A KR 20150024843A KR 20147035652 A KR20147035652 A KR 20147035652A KR 20147035652 A KR20147035652 A KR 20147035652A KR 20150024843 A KR20150024843 A KR 20150024843A
Authority
KR
South Korea
Prior art keywords
lung cancer
small cell
cell lung
clathrin
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR20147035652A
Other languages
English (en)
Korean (ko)
Inventor
첸 덕신
쇼시 테슬러
Original Assignee
테바 파마슈티컬 인더스트리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테바 파마슈티컬 인더스트리즈 리미티드 filed Critical 테바 파마슈티컬 인더스트리즈 리미티드
Publication of KR20150024843A publication Critical patent/KR20150024843A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR20147035652A 2012-05-18 2013-05-17 비소세포 폐암을 치료하는 방법 Withdrawn KR20150024843A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261649092P 2012-05-18 2012-05-18
US61/649,092 2012-05-18
PCT/US2013/041652 WO2013173757A1 (en) 2012-05-18 2013-05-17 Method for treating non-small cell lung cancer

Publications (1)

Publication Number Publication Date
KR20150024843A true KR20150024843A (ko) 2015-03-09

Family

ID=49581824

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20147035652A Withdrawn KR20150024843A (ko) 2012-05-18 2013-05-17 비소세포 폐암을 치료하는 방법

Country Status (17)

Country Link
US (1) US20130310440A1 (https=)
EP (1) EP2849761A1 (https=)
JP (1) JP2015522542A (https=)
KR (1) KR20150024843A (https=)
CN (1) CN104684564A (https=)
AR (1) AR091090A1 (https=)
AU (1) AU2013262589A1 (https=)
BR (1) BR112014028787A2 (https=)
CA (1) CA2874092A1 (https=)
EA (1) EA201492148A1 (https=)
IL (1) IL235459A0 (https=)
IN (1) IN2014DN10390A (https=)
PH (1) PH12014502569A1 (https=)
SG (1) SG11201407649RA (https=)
TW (1) TW201402132A (https=)
UY (1) UY34812A (https=)
WO (1) WO2013173757A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100768109B1 (ko) 1999-02-26 2007-10-17 더 유니버시티 오브 브리티쉬 콜롬비아 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
WO2011143071A2 (en) 2010-05-08 2011-11-17 The Regents Of The University Of California Sem scanner sensing apparatus, system and methodology for early detection of ulcers
WO2012123823A1 (en) 2011-03-15 2012-09-20 The University Of British Columbia Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer
CN104473973B (zh) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 一株戈氏梭菌驯化株的应用
US10182740B2 (en) 2015-04-24 2019-01-22 Bruin Biometrics, Llc Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements
MY194948A (en) * 2016-05-13 2022-12-28 Golden Biotechnology Corp Methods and compositions for treating advanced stage non-small cell lung cancer
MX2019004923A (es) 2017-02-03 2019-06-20 Bruin Biometrics Llc Medicion de la susceptibilidad a ulceras del pie diabetico.
KR102402347B1 (ko) 2017-02-03 2022-05-30 브루인 바이오메트릭스, 엘엘씨 부종의 측정
LT3515296T (lt) 2017-02-03 2024-02-12 Bbi Medical Innovations, Llc Audinio gyvybingumo matavimas
AU2018368709C1 (en) 2017-11-16 2025-07-17 Bruin Biometrics, Llc Providing a continuity of care across multiple care settings
US20190211044A1 (en) * 2018-01-05 2019-07-11 LifeUnit Inc. Adjuvant Chemicals that Prevent Drug Tolerance and Persister Formation by Bacteria
PT3749181T (pt) 2018-02-09 2024-05-15 Bruin Biometrics Llc Deteção de lesões nos tecidos
CA3115263A1 (en) 2018-10-11 2020-04-16 Bruin Biometrics, Llc Device with disposable element
US11642075B2 (en) 2021-02-03 2023-05-09 Bruin Biometrics, Llc Methods of treating deep and early-stage pressure induced tissue damage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
WO2005094899A1 (en) * 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
JP2011525241A (ja) * 2008-06-18 2011-09-15 アボット・ラボラトリーズ ＰｌＧＦ−１コンパニオン診断方法および製品
AU2012257487A1 (en) * 2011-05-19 2014-01-16 Teva Pharmaceutical Industries Ltd. Method for treating non-small cell lung cancer

Also Published As

Publication number Publication date
IL235459A0 (en) 2014-12-31
BR112014028787A2 (pt) 2017-06-27
CA2874092A1 (en) 2013-11-21
WO2013173757A1 (en) 2013-11-21
PH12014502569A1 (en) 2015-01-21
AU2013262589A1 (en) 2015-01-22
UY34812A (es) 2013-12-31
EP2849761A1 (en) 2015-03-25
WO2013173757A8 (en) 2015-04-30
CN104684564A (zh) 2015-06-03
TW201402132A (zh) 2014-01-16
SG11201407649RA (en) 2014-12-30
IN2014DN10390A (https=) 2015-08-14
US20130310440A1 (en) 2013-11-21
AR091090A1 (es) 2014-12-30
EA201492148A1 (ru) 2015-04-30
JP2015522542A (ja) 2015-08-06

Similar Documents

Publication Publication Date Title
KR20150024843A (ko) 비소세포 폐암을 치료하는 방법
US20130017272A1 (en) Method for treating non-small cell lung cancer
Marshall et al. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors
Saxena et al. ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective
US8003105B2 (en) Method of treating cancer by co-administration of anticancer agents
JP2020109112A (ja) 薬物送達および治療用薬剤の有効性を向上させる方法
CN121622695A (zh) 用于治疗癌症的atr抑制剂
KR20130028728A (ko) 암의 치료 방법
Laquente et al. Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model
CN107923918A (zh) 用于开发个性化药物治疗计划和基于蛋白质组谱的靶向药物开发的方法
KR20150126038A (ko) 폐암의 치료 방법
KR20200014298A (ko) Her2 양성 암의 치료
CN107750165A (zh) 借助塞里班土单抗的组合治疗
Ritch et al. Phase II study of PKC-α antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer
Seiden et al. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors
KR20200110452A (ko) 담도암을 치료하기 위한 방법 및 조합 요법
Raninga et al. Thioredoxin reductase 3 inhibition sensitizes triple-negative breast cancer cells to EGFR inhibitors
Herbst et al. A Randomized, Phase III Study of Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab Investigating EGFR FISH in Patients with Advanced Non-Small Cell Lung Cancer: SWOG S0819

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000